Restoring lipid homeostasis to redefine Alzheimer’s disease.
MCM6 is an early-stage biotechnology company developing differentiated small-molecule and antisense oligonucleotide (ASO) therapeutics. Backed by an STTR grant from the National Institute on Aging (NIA/NIH), we are advancing disease-modifying candidates in a multi-billion-dollar market with profound unmet need.
MCM6 is pioneering targeted therapeutics to address the core mechanistic driver of Alzheimer’s in APOE4 carriers—the largest genetic risk group.
Our Story
In 1906, Dr. Alois Alzheimer identified the neuropathological hallmarks of the disease that now bears his name—a devastating condition marked by lipid dysregulation and one of humanity’s most profound medical and societal challenges. MCMVI, the Roman numeral for that pivotal year, embodies the founding spirit of MCM6. We confront these challenges through innovative science and restore hope for patients and families worldwide.
Our Mission
MCM6 is an early-stage biotechnology company driven by a bold vision: to redefine Alzheimer’s disease and related cognitive impairments by restoring lipid homeostasis. We are dedicated to delivering transformative, precision therapeutics that address the root causes of neurodegeneration.
Pipeline & Momentum
Platform Capabilities: High-content screening (HCS) in human APOE4 iPSC-derived neurons, with advanced validation in the miBRAIN 3D system.
Current Progress: Identified druggable targets using our platform, and target validation and lead optimization are underway, supported by non-dilutive NIA/NIH STTR funding.
Next Milestones: Selection of preclinical candidate(s), IND-enabling studies, Strategic partnerships to accelerate clinical development. MCM6 is advancing a portfolio of candidates with the potential to become first-in-class disease-modifying therapies for APOE4-associated Alzheimer’s disease.
Leadership & Collaborators
Kelvin Lam, Co-Founder. A leading expert in drug discovery, Dr. Lam guides target selection, lead optimization, and preclinical validation for MCM6’s therapeutic programs.
Matthew Stremlau, Co-Founder. A distinguished scientist, Dr. Stremlau leads the strategic translation of APOE4 biology into targeted therapeutics for Alzheimer’s disease and related disorders.
Miranda Yang, Co-Founder. & Assistant Professor. An advisor in platform engineering, Dr. Yang plays a pivotal role in developing and integrating all six major brain cell types into MCM6’s proprietary 3D miBRAIN system and provides strategic scientific guidance.
Joel Blanchard, Advisor & Associate Professor. MCM6 was built upon the foundational scientific contributions of the Blanchard Lab at the Icahn School of Medicine at Mount Sinai. Professor Blanchard continues to provide strategic scientific guidance to the company. MCM6 collaborates closely with world-renowned experts in neuroscience and bioengineering.
Investment Opportunity
MCM6 offers accredited investors a compelling entry point into precision neuroscience, featuring proprietary technology and clear translational objectives: Validated science and a highly human-relevant platform, a focused mechanistic approach targeting the largest genetically defined Alzheimer’s risk group (APOE4 carriers), superior translational models with strong commercial scalability, and advancing toward IND submission with defined capital requirements. We invite qualified investors to partner with MCM6 in transforming the future of Alzheimer’s treatment.
